CN106692314A - Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis - Google Patents
Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis Download PDFInfo
- Publication number
- CN106692314A CN106692314A CN201610997036.0A CN201610997036A CN106692314A CN 106692314 A CN106692314 A CN 106692314A CN 201610997036 A CN201610997036 A CN 201610997036A CN 106692314 A CN106692314 A CN 106692314A
- Authority
- CN
- China
- Prior art keywords
- preparation
- food
- eluent
- medicine
- hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 201000005569 Gout Diseases 0.000 title claims abstract description 33
- 239000000178 monomer Substances 0.000 title claims abstract description 25
- 210000000582 semen Anatomy 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000003480 eluent Substances 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000013373 food additive Nutrition 0.000 claims abstract description 8
- 239000002778 food additive Substances 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- 230000003068 static effect Effects 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 36
- 235000015266 Plantago major Nutrition 0.000 claims description 36
- 240000008790 Musa x paradisiaca Species 0.000 claims description 31
- 241001499733 Plantago asiatica Species 0.000 claims description 12
- 229930182470 glycoside Natural products 0.000 claims description 12
- 150000002338 glycosides Chemical class 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 241001122767 Theaceae Species 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 12
- 229940116269 uric acid Drugs 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 241000234295 Musa Species 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241001436679 Adama Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000601164 Clematis orientalis Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000009357 ermiao Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis. The method comprises the following steps of: weighing a certain mass of raw materials such as semen plantaginis and breaking the seed coat, adding ethanol in an amount of 30 times for performing reflux extraction for 2 times, wherein the extraction time each time is 1.5 hours; performing reduced pressure recovery on ethanol solution, centrifuging the concentrated solution at a high speed so as to obtain the filtrate, passing through an AB-8 type macroporous resin column, performing static adsorption for 2 hours, eluting with 10BV water, removing the eluent, sequentially eluting the ethanol of different concentrations from a lower concentration to a higher concentration, collecting the eluent of a target compound with high duty cycle, merging, and preparing the eluent into the product. According to the method disclosed by the invention, the eluent is prepared into different products comprising capsules, tablets, mixtures, drug/food additives and health tea, and the method is simple in preparation, safe, non-toxic, obvious in drug efficiency and convenient to use and does not have any side effect.
Description
Technical field
The system for preventing and treating hyperuricemia and gout medicine-food two-purpose monomer is extracted from plantain seed the invention particularly relates to a kind of
Preparation Method.
Background technology
After the eighties in 20th century, with the raising of economic life level, dietary structure there occurs change with habits and customs,
So that hyperuricemia is in cumulative year after year trend with the incidence of disease of gout, domestic and foreign scholars have carried out substantial amounts of research to it,
Epidemiology aspect, the incidence of disease of hyperuricemia is because of race and variant from different places, not consistent, China of report of various countries
Up to 0.26%~0.34%, the incidence of disease of hyperuricemia is up to 5.78%~13.8%, the adjoint height of gout for the gout incidence of disease
Uricacidemia also has become one of coronary heart disease, important risk factor of hypertension.
Gu Ping[1]Randomly selecting the data in Guangdong People's Hospital's people taking physical examination 26621 in 2004 carries out urine high
The incidence statistical analysis of acidaemia illness rate and relevant disease.The illness rate of hyperuricemia is 21.8%, male's illness rate
It is significantly higher than women.The incidence such as hyperlipidemia, hypertension, hyperglycaemia, coronary heart disease, fatty liver is significantly higher than in hyperuricemia
Blood uric acid normal group.Red legend China etc.[2]The hyperuricemia that 1249 bodies of MEC find is carried out with high fat of blood and obesity
Analysis, wherein blood uric acid increases 364, accounts for 29.1%, and hyperlipidemia 325 accounts for 89.2%, and overweight 279 is accounted for
76.6%, hence it is evident that higher than normal group, and have significant difference.As can be seen here as purine metabolic disturbance primary gout not only
With the age, it is also closely related with hypertension, high fat of blood, diabetes, coronary heart disease, obesity etc..
Prevention to hyperuricemia and gout at present is mainly limitation purine food high, and control is drunk, in treatment both
The arthritis of acute attack is controlled, again long-term treatment hyperuricemia, prevent tophaceous deposition.Currently used for treatment gout
The arthritic chemicals of property has colchicin, non-steroid anti-inflammatory drug, glucocorticoid, and they can soon and effectively alleviate pain
Bitterly, reduce inflammation；Correcting the chemicals of hyperuricemia has probenecid, Benzbromarone (promoting the excretion of uric acid) and other purine
Alcohol (suppresses the generation of uric acid), but these adverse drug reactions are more, and Benzbromarone can cause serious hepatic lesion and nerveous system
System adverse reaction, allopurinol can cause the secondary work of the poison such as super quick allergy syndrome of allergic, hepatic injury, life-threatening
With.Chinese medicine such as Bi Collettii, the bark of ash, Bai Ai, globe artichoke, the root of Chinese clematis, plantain seed, golden cypress, desmodium, bark of ash etc. have certain anti-trioxypurine
Effect, is clinically usually used in the prevention and treatment of urarthritis and hyperuricemia, and develop giant knotweed gout granules, pain
The patent medicine such as wind instant granule for curing, ERMIAO PILL, Punching line.
[1] Gu Ping Guangzhous Check-up crowd blood uric acid disease disease condition high and relevant disease analysis [J] Tropical China doctors
Learn, 2006,6 (6):1082-1084.
[2] red legend China, Chen Leiqian, just strive waiting blood uric acid diseases high pre- with blood fat, Obesity Related Factors analysis [J] Zhejiang
Anti- medical science, 2004,16 (12):70-74.
The content of the invention
For adverse reaction during above-mentioned chemicals use is more, Chinese medicine in-convenience in use and taking dose it is big etc. ask
Topic, the present invention provides a kind of medicine-food two-purpose list for preventing and treating hyperuricemia and gout that consumption is small, easy to use, adverse reaction is few
Body.
The purpose of the present invention will be achieved through the following technical solutions：One kind from plantain seed extract prevent and treat hyperuricemia and
The preparation method of gout medicine-food two-purpose monomer, comprises the following steps：Raw material plantain seed 500g is weighed, is struck and is broken in the seed coat, plus 30 times of amounts
60% alcohol reflux is extracted 2 times, and each 1.5h is recovered under reduced pressure ethanol, and high speed centrifugation concentrate obtains filtrate, upper AB-8 types macropore
Resin column, Static Adsorption 2 hours, uses 10BV water elutions, discards eluent, and different concentration ethanol is eluted successively from low to high, receives
Eluent of the collection with accounting target compound high simultaneously merges, and gained eluent is prepared into product.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, described plantain seed includes Asiatic plantain glycosides A, Asiatic plantain glycosides B, Asiatic plantain glycosides C, Asiatic plantain glycosides D, Asiatic plantain glycosides E, Asiatic plantain
Glycosides F.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the quality of the plantain seed is 500g~1000g.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the product of the eluent processing includes capsule, tablet, mixture, medicine/food additives and health protection tea.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the preparation method of the capsule is：Gained eluent is vacuum dried or is spray-dried to obtain fine powder, adds 20% starch
30mL, pelletizes encapsulated.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the preparation method of the tablet is：Gained eluent is vacuum dried or is spray-dried to obtain fine powder, adds 25mL 20% to form sediment
Paste mixing, 10mL 5%PVP (PVP) ethanol, granulation, drying, compressing tablet.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the preparation method of the mixture is：Gained eluent concentrates or is diluted to the medicinal extract of relative density 1.2, and bottling makes mouth
Take liquid.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the preparation method of the medicine/food additives is：Gained eluent be concentrated into relative density 1.2 or vacuum drying or
Fine powder is spray-dried to obtain, as medicine/food additives.
Preferably, described a kind of extraction from plantain seed prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method, the preparation method of the health protection tea is：Gained eluent is concentrated into relative density 1.2, with Tie Guanyin tea by volume
It is 1：25 mixing, dry 8 hours under the conditions of being placed in 55 DEG C, then are ground into 20 mesh, sterilization packaging storage, are made the drop urine of the bags of 6g mono-
Sour health protection tea.
The beneficial effects of the invention are as follows：The present invention is prepared into different products, including capsule, piece by by eluent
Agent, mixture, medicine/food additives and health protection tea, its preparation method are simple, and safety non-toxic, in the absence of side effect, drug effect
Substantially, it is easy to use.
Specific embodiment
To more fully understand the present invention, further specific elaboration is made to the present invention below by following examples, but not
Limitation of the invention is can be regarded as, it is nonessential according to some that foregoing invention content is made for those skilled in the art
Improve and adjust, be also considered as being within the scope of the present invention.
Embodiment 1：Effect of the present invention to hyperuricemia and gouty
Experimental animal：KM mouse, SPF grades, male, body weight 18-22g is carried by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center
For normal raising supplies examination after 3 days.
Medicine and reagent：Plantain seed (Guangzhou Medicinal Material Co., Ltd. Traditional Chinese Medicinal Tablet Factory)；Adenine (lot number：Z00070608), extensively
Qi Yun Bioisystech Co., Ltd of state city；Oteracil Potassium (lot number：T4514), Adamas-beta (Adama this-beta company)；
Allopurinol (friendship everything limited company of upper Hisense, lot number：100583)；Uric acid reagent box (lot number：20110314) Nanjing
Build up Bioengineering Research Institute；Urea nitrogen kit (lot number：20110225) Bioengineering Research Institute is built up in Nanjing；Creatinine reagent
Box (lot number：20110311) Bioengineering Research Institute is built up in Nanjing.
It is a kind of that the preparation method for preventing and treating hyperuricemia and gout medicine-food two-purpose monomer is extracted from plantain seed including following
Step：Plantain seed 1000g is weighed, is struck and is broken in the seed coat, 30 times of 60% alcohol refluxs of amount are extracted 2 times, and each 1.5h is recovered under reduced pressure ethanol
Liquid, high speed centrifugation concentrate obtains filtrate, and upper AD-8 types macroporous resin column, Static Adsorption 2 hours uses 10BV water elutions, discards and wash
De- liquid, different concentration ethanol is eluted successively from low to high, is collected the eluent with accounting target compound high and is merged, vacuum
Concentration, is vacuum dried or is spray-dried and to obtain fine powder, is configured to required concentration with distilled water before use.
According to clinic adult daily dosage 0.15g/60kg and animal kilogram dosage conversions Y-factor method Y converse the present invention it is low,
The dosage of middle and high dosage group, i.e. low dosage are administered by 0.08g/kg/d, and middle dose group is administered by 0.16g/kg/d, high dose group
It is administered by daily 0.32g/kg/d, allopurinol 0.04g/kg/d administrations.
Using adenine gavage and Oteracil Potassium intraperitoneal injection use in conjunction, hyperuricemia mouse model is caused.
SPF grades of Male Kunming strain mice 60 is taken, weight 18-22g is randomly divided into 6 groups, i.e., high, medium and low dosage group of the invention, model
Control group, blank control group and allopurinol group.Every group 10.Blank control group and the daily gavage of model control group give equivalent
Distilled water, remaining each group was according to concentration gastric infusion, totally 14 days.In addition to blank control group, in the 10-14 days gavages after administration
Adenine (50mg/kg) is given, in 1h after last dose, intraperitoneal injection Oteracil Potassium (300mg/kg).2h eye sockets take after injection
Blood system is operated from serum according to kit explanation.Serum uric acid, urea nitrogen, its result of the test such as table 1 below institute are determined respectively
Show：
Influence (`x ± s) of the Chinese prescription of table 1 to hyperuricemia mice serum uric acid content
Note：* P ＜ 0.01 compared with model group control group.▲ compared with blank control group P ＜ 0.05.
The result of table 1 shows, compared with blank control group, model control group mice serum uric acid content significantly increases (P<
0.05), illustrate that hyperuricemia model is successfully established.Compare with model control group, the basic, normal, high each dosage of the present invention, other purine
Alcohol group can significantly reduce high lithemia disease mice serum uric acid content (P<0.01), each dosage group of the invention and allopurinol group ratio
Compared with difference is not statistically significant (P>0.05).
Influence ((`x ± s) of the Chinese prescription of table 2 to hyperuricemia mice serum urea nitrogen content
Note：* P ＜ 0.01 compared with model group control group.▲ compared with blank control group P ＜ 0.01.
The result of table 2 shows, compared with blank control group, the significantly raised (P of model control group urea nitrogen content<0.01), originally
Invention high dose group significantly reduces the content (P of urea nitrogen in hyperuricemia mice serum<0.01).Low dosage of the present invention, in
Dosage group and allopurinol group have no significant effect (P to high lithemia disease mice serum urea nitrogen content>0.05).
Shown by above analysis of experiments：The effect that the present invention has to be reduced uric acid, improve gouty nephropathy.
Embodiment 2：Acute toxicity testing of the invention
Experimental animal：KM mouse, SPF grades, male, body weight 18-22g is carried by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center
For.Normal raising supplies examination after 3 days.
Medicine and reagent：Plantain seed (Guangzhou Medicinal Material Co., Ltd. Traditional Chinese Medicinal Tablet Factory)；
A kind of extraction from plantain seed of the present invention prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method：Plantain seed 500g is weighed, is struck and is broken in the seed coat, 30 times of 60% alcohol refluxs of amount are extracted 2 times, and each 1.5h is recovered under reduced pressure ethanol
Liquid, high speed centrifugation concentrate obtains filtrate, and upper AD-8 types macroporous resin column, Static Adsorption 2 hours uses 10BV water elutions, discards and wash
De- liquid, different concentration ethanol is eluted successively from low to high, is collected the eluent with accounting target compound high and is merged, vacuum
Concentration, is vacuum dried or is spray-dried and to obtain fine powder, is configured to required concentration with distilled water before use.
KM mouse 80 are taken, four groups are equally divided into, fasting 10h before gavage prohibits water 6h.Daily gavage twice, every time
0.6mL, continuous 7 days.Medicine small dose group of the present invention：Dosage is 0.30g/kg/d, equivalent to 60 times of people's consumption；Medicine of the present invention
Thing middle dose group：Dosage is 3.00g/kg/d, equivalent to 600 times of people's consumption；Drug bolus group of the present invention：Dosage is
15.0g/kg/d, equivalent to 3000 times of people's consumption；Control group：Give equivalent distilled water.
Experimental result：7 days mouse of experiment are all survived, and appetite is reduced in rarely seen animal administration 5h, and activity weakens, medicine color
Semiliquid stool etc., recovers normal after drug withdrawal.4 groups of animals drinking-water, hair color, body weight, excrement and the heart, liver, spleen, lung, kidney, thymus gland, brain,
The aspects such as form, size, the smoothness of main organs such as tongue, stomach, intestines, bladder, sexual gland (uterus, ovary or testis and epididymis) are
No significant difference.Described above, toxic and side effect of the present invention is small, and because by drug concentration and volumetric constraint, can not find and cause small
The dead dosage of mouse, therefore LD50 of the invention cannot be measured.Mouse maximum dosage-feeding is 15.0g/kg/d, equivalent to people's consumption
3000 times.
Experiment conclusion：Long term toxicity test of the present invention shows safety non-toxic.
Embodiment 3：Long term toxicity test of the invention
Experimental animal：KM mouse, SPF grades, male, body weight 18-22g is carried by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center
For.Normal raising supplies examination after 3 days.
Medicine and reagent：Plantain seed (Guangzhou Medicinal Material Co., Ltd. Traditional Chinese Medicinal Tablet Factory).
A kind of extraction from plantain seed of the present invention prevents and treats the preparation of hyperuricemia and gout medicine-food two-purpose monomer
Method：Weigh plantain seed 1000g, 30 times of 60% alcohol refluxs of amount are extracted 2 times, and each 1.5h is recovered under reduced pressure ethanol, at a high speed from
Heart concentrate obtains filtrate, and upper AD-8 types macroporous resin column, Static Adsorption 2 hours uses 10BV water elutions, discards eluent, different
Concentration ethanol is eluted successively from low to high, is collected the eluent with accounting target compound high and is merged, and is concentrated in vacuo, vacuum
Dry or be spray-dried to obtain fine powder, be configured to required concentration with distilled water before use.
KM mouse 80 are taken, four groups are equally divided into, fasting 10h before gavage prohibits water 6h.Daily gavage twice, every time
0.6mL, continuous 14 days, observes 14 days again after drug withdrawal.Medicine small dose group of the present invention：Dosage is 0.08g/kg/d, equivalent to people
30 times of consumption；Medicine middle dose group of the present invention：Dosage is 0.16g/kg/d, equivalent to 60 times of people's consumption；Medicine of the present invention is big
Dosage group：Dosage is 0.32g/kg/d, equivalent to 120 times of people's consumption；Control group：Give equivalent distilled water.
Result of the test：Appetite is reduced in each group mouse species administration 5h, and activity weakens, medicine color semiliquid stool etc., extensive after drug withdrawal
It is multiple normal.Average weight of each test group when the 14th day after 14d being administered and being discontinued is compared with control group without significant difference (P>
0.05)。
Erythrocytes, total white blood cells, content of hemoglobin, the platelet count of test group mouse are the 1st day after drug withdrawal
And be discontinued after the 14th day compared with control group without significant difference (P>0·05).The serum glutamic pyruvic transminase of each test group mouse,
Glutamic-oxalacetic transaminease, alkaline phosphatase after the drug withdrawal the 1st day and after being discontinued the 14th day compared with control group without significant difference (P>
0.05)。
The 1st day and the 14th day after drug withdrawal, cut open inspection is shown in form, color, the quality of each group heart, liver, spleen, lung, kidney, stomach and intestines
Normally.Histopathologic examination, high, medium and low dosage group of the invention and control group mice are showed no obvious pathological change.
Conclusion (of pressure testing)：Subacute toxicity test of the present invention shows safety non-toxic.
Presently preferred embodiments of the present invention is the foregoing is only, is not intended to limit the invention, it is all in essence of the invention
Within god and principle, any modification, equivalent substitution and improvements made etc. should be included within the scope of the present invention.
Claims (9)
1. a kind of that the preparation method for preventing and treating hyperuricemia and gout medicine-food two-purpose monomer is extracted from plantain seed, its feature exists
In comprising the following steps：Certain mass raw material plantain seed 500g is weighed, is struck and is broken in the seed coat, plus 30 times of 60% alcohol refluxs of amount extract 2
Secondary, each 1.5h is recovered under reduced pressure ethanol, and high speed centrifugation concentrate obtains filtrate, upper AB-8 types macroporous resin column, Static Adsorption 2
Hour, 10BV water elutions are used, eluent is discarded, different concentration ethanol is eluted successively from low to high, and collecting has accounting target high
The eluent of compound simultaneously merges, and gained eluent is prepared into product.
2. a kind of extraction from plantain seed according to claim 1 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that：Described plantain seed include Asiatic plantain glycosides A, Asiatic plantain glycosides B, Asiatic plantain glycosides C, Asiatic plantain glycosides D,
One or more in Asiatic plantain glycosides E, Asiatic plantain glycosides F.
3. a kind of extraction from plantain seed according to claim 1 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that：The quality of the plantain seed is 500g~1000g.
4. a kind of extraction from plantain seed according to claim 1 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that：The product of the eluent processing includes capsule, tablet, mixture, medicine/food additives
And health protection tea.
5. a kind of extraction from plantain seed according to claim 4 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that the preparation method of the capsule is：Gained eluent is vacuum dried or is spray-dried carefully
Powder, adds 20% starch 30mL, pelletizes encapsulated.
6. a kind of extraction from plantain seed according to claim 4 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that the preparation method of the tablet is：Gained eluent is vacuum dried or is spray-dried to obtain fine powder,
Add the gelatinized corn starches of 25mL 20%, 10mL 5%PVP (PVP) ethanol, granulation, drying, compressing tablet.
7. a kind of extraction from plantain seed according to claim 4 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that the preparation method of the mixture is：Gained eluent concentrates or is diluted to relative density 1.2
Medicinal extract, bottling makes oral liquid.
8. a kind of extraction from plantain seed according to claim 4 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that the preparation method of the medicine/food additives is：Gained eluent is concentrated into relative density
1.2 are vacuum dried or are spray-dried to obtain fine powder, used as medicine/food additives.
9. a kind of extraction from plantain seed according to claim 4 prevents and treats hyperuricemia and gout medicine-food two-purpose monomer
Preparation method, it is characterised in that the preparation method of the health protection tea is：Gained eluent is concentrated into relative density 1.2, is seen with iron
Sound tealeaves is by volume 1：25 mixing, dry 8 hours under the conditions of being placed in 55 DEG C, then are ground into 20 mesh, sterilization packaging storage, system
Into the anti-trioxypurine health protection tea of the bags of 6g mono-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610997036.0A CN106692314A (en) | 2016-11-14 | 2016-11-14 | Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610997036.0A CN106692314A (en) | 2016-11-14 | 2016-11-14 | Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106692314A true CN106692314A (en) | 2017-05-24 |
Family
ID=58940843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610997036.0A Pending CN106692314A (en) | 2016-11-14 | 2016-11-14 | Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692314A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102311466A (en) * | 2011-08-23 | 2012-01-11 | 北京科莱博医药开发有限责任公司 | Method for extracting phenylethanoid glycoside active components from semenplantaginis |
| CN102895320A (en) * | 2012-04-16 | 2013-01-30 | 全金花 | Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout |
| CN104800690A (en) * | 2015-04-20 | 2015-07-29 | 黄冈市中医医院 | Traditional Chinese medicine for reducing uric acid and preparation method thereof |
-
2016
- 2016-11-14 CN CN201610997036.0A patent/CN106692314A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102311466A (en) * | 2011-08-23 | 2012-01-11 | 北京科莱博医药开发有限责任公司 | Method for extracting phenylethanoid glycoside active components from semenplantaginis |
| CN102895320A (en) * | 2012-04-16 | 2013-01-30 | 全金花 | Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout |
| CN104800690A (en) * | 2015-04-20 | 2015-07-29 | 黄冈市中医医院 | Traditional Chinese medicine for reducing uric acid and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 皮璟渔等: "大粒车前子苯乙醇苷提取物的精制及降血尿酸作用", 《食品工业科技》 * |
| 郑秀棉等: "车前子的化学成分与药理活性研究进展", 《中药材》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
| CN112121144B (en) * | 2020-09-20 | 2021-11-12 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
| CN106943423A (en) | The polysaccharide composition acted on regulating intestinal canal Bacterial community and its application | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN105919136A (en) | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof | |
| CN102793741A (en) | Beautiful millettia root extract and application thereof | |
| CN101474375B (en) | Compound Cordyceps militaris L. Link preparation and production method and application | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN102907606A (en) | Beta-glucan composition and application thereof | |
| CN104432063B (en) | Composition for alleviating athletic fatigue and preparation method thereof | |
| CN101011432B (en) | Use of extract of bracken flavone as medicament for lead expelling and lead poisioning alleviation | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN106692314A (en) | Preparation method for extracting medical and edible dual-purpose monomers for preventing and treating hyperuricemia and gout from semen plantaginis | |
| CN112741851A (en) | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules | |
| CN106727857A (en) | It is a kind of that the preparation method for preventing and treating hyperuricemia and gout medicine-food two-purpose monomer is extracted from Semen Cuscutae | |
| CN107669763B (en) | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof | |
| CN104622971A (en) | Pharmaceutical composition for resisting diabetes activity and preparation method thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN104857180B (en) | Composition for resisting fatigue and improving immunity and preparation method and application thereof | |
| CN103735575A (en) | Rhamnella gilgitica extract and preparation method and application thereof | |
| AU2016313671A1 (en) | Health food and process for preparing the same | |
| CN101361799B (en) | Composition containing brown alga polysaccharide sulfuric ester and schisandra chinensis and use thereof | |
| CN102488841B (en) | Capsule or tablet for assisting memory improvement and preparation method thereof | |
| CN101491649B (en) | Ginseng and astragalus pollen tablet and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170808 Address after: 510000 Tianhe District, Guangdong, No. five road, No. 381, Applicant after: Zhang Qingzhong Address before: Wushan Technology Plaza 373 No. 510000 Guangdong province Guangzhou city Tianhe District road five Applicant before: Guangzhou carpenter Technology Co., Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |